Clinical trials: Human Papillomavirus Virus
Cervical Cancer
Long-Term Follow-Up of HPV FOCAL Participants
This FOCAL follow-up study aims to assess the long-term effectiveness and safety of primary HPV testing for cervical cancer screening.
- Trial name
- HPV FOCAL (NCT04185389)
- Testing
- HPV and cytology co-testing (via Liquid based collection device)
- Where
- Canada
- Volunteers
- 1,710 people
- Sponsor
- University of British Columbia
HPV, Human Papilloma Virus
HPV Infections, Cancer of the Vulva and Therapeutical Success
HPV infections may be responsible for different types of cancer in females. Primary Goal of the study was to identify the prevalence of an hpv affiliation in retrospective-prospective analysed cohort of patients who suffer from…
- Trial name
- NCT03082950
- Testing
- polymerase chain reaction
- Where
- Germany
- Volunteers
- 110 people
- Sponsor
- University of Luebeck
Low-Grade Intraepithelial Neoplasia of Cervix
Evaluation of Oral EGCG Treatment for L-SIL Associated With HPV Infection
The study aims to evaluate the effectiveness of the synergy of oral Epigallocatechin Gallate as a treatment for Low-grade Cervical Lesions (L-SIL) associated with Human Papilloma Virus (HPV) infection.
- Trial name
- EGCG-HPV (NCT06314113)
- Testing
- Epigallocatechin Gallate
- Where
- Italy
- Volunteers
- 50 people
- Sponsor
- University of Palermo
Human Papilloma Virus Infection
Post-Licensure Study of the Safety of GARDASIL™ in Males (V501-070)
This is a post-licensure safety observation cohort study to describe the general safety of GARDASIL™ (a quadrivalent human papillomavirus vaccine) in males.
- Trial name
- NCT01567813
- Volunteers
- 114,035 people, healthy volunteers welcome
- Sponsor
- Merck Sharp & Dohme LLC
Human Papilloma Virus, Human Immunodeficiency Virus
Use of ACU-D1 in HPV Associated Vulvar and Perianal Lesions in People With HIV
The goal of this study is to test the maximum tolerated dose of ACU-D1 in HIV-positive people with HPV-associated vulvar and perianal lesions.
- Conditions
- Human Papilloma Virus, Human Immunodeficiency Virus, Anal Intraepithelial Neoplasia, High-Grade Squamous Intraepithelial Lesions
- Trial name
- NCT06233331
- Testing
- Dose Level 1 ACU-D1 ointment, Dose Level 2 ACU-D1 ointment, Dose Level 3 ACU-D1 ointment
- Where
- United States
- Volunteers
- 9 people
- Sponsor
- Emory University
Papillomavirus Infections
Effect of Oral Papilozumib on Vaginal and Intestinal Microbiota in Human Papillomavirus (HPV)-Positive Women
This open-label, single-group study evaluated the effects of a 3-month oral synbiotic dietary supplement on vaginal and intestinal microbiota in women with a positive human papillomavirus (HPV) test.
- Trial name
- NCT07755566
- Testing
- Papilozumib
- Where
- Spain
- Volunteers
- 21 people
- Sponsor
- Hifas da Terra S.L.
Human Papillomavirus Infection, Human Papillomavirus-Related Malignant Neoplasm
ESCUDDO Long Term Follow Up
This phase IV trial evaluates the long term protection provided by either one or two doses of the 9v human papillomavirus (HPV) vaccine for participants who were part of the ESCUDDO study.
- Trial name
- ESCUDDO LTFU (NCT07706673)
- Testing
- Diphtheria Toxoid/Tetanus Toxoid/Acellular Pertussis Vaccine Adsorbed, Recombinant Human Papillomavirus Nonavalent Vaccine
- Where
- Costa Rica
- Volunteers
- 13,700 people, healthy volunteers welcome
- Sponsor
- National Cancer Institute (NCI)
HIV Infection
Correlates of Oral Human Papillomavirus Infection in Adolescents and Young Adults With Behaviorally Acquired HIV
The proposed study is a substudy of ATN 106 and a cross sectional study intended to be conducted at each of the AMTUs newly participating in ATN III.
- Trial name
- NCT01492842
- Where
- 5 sites in United States
- Volunteers
- 272 people
- Sponsor
- University of North Carolina, Chapel Hill
Cervical Cancer, Genital Warts
Alternate Dosing Schedules Study for HPV Vaccine (ADS)
The purpose of this study was to determine if delayed dosing of recombinant human papillomavirus (HPV) quadrivalent (Types 6, 11, 16, and 18) vaccine in 9-18 year old girls elicited an equivalent immune response (geometric mean…
- Trial name
- ADS (NCT02280642)
- Testing
- Both 2nd and 3rd doses on time, 2nd dose late and 3rd dose on time, 2nd dose on time and 3rd dose late
- Where
- 3 sites in United States
- Volunteers
- 331 people, healthy volunteers welcome
- Sponsor
- Duke University
Human Papillomavirus Vaccine, Chronic Condition
Evaluation of Human Papillomavirus Vaccine Coverage in Girls and Young Women With Chronic Disease
The main objective of the study is to determine the vaccination coverage rate for human papillomavirus in adolescents aged 11 to 20 with chronic disease and treated at the Necker-Enfants Malades Hospital, compared to a population…
- Trial name
- MC-HPV (NCT06158802)
- Testing
- Questionnaire
- Where
- 2 sites in France
- Volunteers
- 223 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
HPV Infection
Human Papillomavirus Anal Infection
Human papillomavirus (HPV) are involved in up to 95 % of anal canal neoplastic lesions. Little is known about HPV carriage in anal canal previous to cancer occurrence in the population and pre-neoplastic lesions, and their risk…
- Trial name
- PAPILLAN (NCT02862795)
- Testing
- HPV detection in anal canal samples
- Where
- 2 sites in France
- Volunteers
- 500 people
- Sponsor
- Centre Hospitalier Universitaire de Besancon
Cervical Inflammation and Human Papilloma Virus Performance
"Performance of HPV DNA Test in Presence of Co-infection With Common RTIs"
There is a strong causal association between persisting genital tract infection with Human Papilloma Virus (HPV) and gradual progression of infection to cervical (mouth of uterus) cancer.The robust study from India have shown…
- Trial name
- NCT02830230
- Testing
- Tab cefixime,Tab Azithromycin
- Where
- India
- Volunteers
- 508 people, healthy volunteers welcome
- Sponsor
- Tata Memorial Hospital
Cervical Cancer, Vulvar Cancer
Education, Immigration and HPV Vaccination: an Informational Randomized Trial
Counteracting misinformation on childhood vaccines remains a priority for public health in industrialized countries. Previous research showed that misinformation-induced vaccine hesitancy particularly concerns very highly or very…
- Conditions
- Cervical Cancer, Vulvar Cancer, Anus Cancer, Penis Cancer
- Trial name
- NCT04905030
- Testing
- Information T1, Information T2, Information C
- Where
- Sweden
- Volunteers
- 2,500 people, healthy volunteers welcome
- Sponsor
- Karolinska Institutet
Cervical Intraepithelial Neoplasia, Cervical Cancer
The Durability of Protection Study of a Recombinant HPV 16/18 Bivalent Vaccine in Female
The primary objective of this study is to evaluate the durability of protection of Recombinant Human Papillomavirus Bivalent (Types 16,18) Vaccine administered in females aged 18-45 years.
- Conditions
- Cervical Intraepithelial Neoplasia, Cervical Cancer, Vaginal Intraepithelial Neoplasia, Vulvar Intraepithelial Neoplasia
- Trial name
- NCT04969445
- Testing
- Recombinant Human Papillomavirus Bivalent (Types 16, 18) Vaccine (Escherichia coli)
- Where
- China
- Volunteers
- 647 people
- Sponsor
- Jun Zhang
Human Papillomavirus
Evaluation of a Novel Point-of-Care Diagnostic Test for Human Papillomavirus (HPV)
To learn if new HPV tests can provide the same results as standard HPV tests. The findings from this study may aid in the development of new HPV tests that require less equipment and are more accessible.
- Trial name
- NCT06434337
- Testing
- Novel point-of-care diagnostic test for detecting HPV ("Rice HPV test")
- Where
- United States
- Volunteers
- 600 people
- Sponsor
- M.D. Anderson Cancer Center
Human Papillomavirus-Related Carcinoma
Human Papillomavirus Education Programs
This clinical trial aims to implement a culturally-tailored educational outreach actives with the goal of increasing knowledge of human papillomavirus (HPV) types that can lead to cancer and uptake of the available vaccine.
- Trial name
- NCT04880837
- Testing
- Educational Intervention, Informational Intervention, Survey Administration
- Where
- United States
- Volunteers
- 12 people, healthy volunteers welcome
- Sponsor
- Ohio State University Comprehensive Cancer Center
Cancer of the Cervix, Cervical Intraepithelial Neoplasia
Compass - Randomised Controlled Trial of Primary HPV Testing for Cervical Screening in Australia
Compass is a randomised controlled trial of primary HPV testing for cervical cancer screening in Australia. A pilot study involving 5,000 women was carried out in 2013-2014.
- Trial name
- Compass (NCT02328872)
- Testing
- Molecular testing for HPV, Liquid Based Cytology
- Where
- Australia
- Volunteers
- 76,181 people, healthy volunteers welcome
- Sponsor
- VCS Foundation
Human Papilloma Virus, Infertility, Female
Impact of Human Papillomavirus Carriage on IVF/ICSI Results (HPV AMP)
The prevalence of the papilloma virus in the general population is 12%. This virus is known to impair male fertility but its impact on female infertility remains uncertain.
- Trial name
- HPV-AMP (NCT06550531)
- Where
- France
- Volunteers
- 618 people
- Sponsor
- University Hospital, Brest
Cervical Cancer, Condylomata Acuminata
An Immuno-bridging Study of a Nonavalent HPV Vaccine (E.Coli) in Healthy Population Aged 9-17 vs Aged 18-26 Years Old
This is a open label clinical trial to evaluate the safety and immunogenicity of a Recombinant Human Papillomavirus Nonavalent (Types 6,11,16,18,31,33,45,52,58)Vaccine(E.Coli) manufactured by Xiamen Innovax Biotech CO., Ltd., in…
- Trial name
- NCT05056402
- Testing
- 3 doses of the Recombinant Human Papillomavirus Nonavalent (Types 6,11,16,18,31,33,45,52,58 )Vaccine(E.Coli), 2 doses of theRecombinant Human Papillomavirus Nonavalent (Types 6,11,16,18,31,33,45,52,58 )Vaccine(E.Coli)
- Where
- China
- Volunteers
- 1,382 people, healthy volunteers welcome
- Sponsor
- Xiamen University
Infections, Papillomavirus, Papillomavirus Vaccines
Immunogenicity and Safety of a Commercially Available Vaccine Co-administered With GSK HPV Vaccine (580299)
Infection with human papillomavirus (HPV) has been clearly established as the necessary cause of cervical cancer. The current Phase 3b study is designed to assess the immunogenicity and safety of a commercially available vaccine…
- Trial name
- NCT00637195
- Testing
- Subjects received 3 doses of GSK Biologicals' HPV vaccine (580299) (Cervarix™), Engerix™
- Where
- 2 sites in Belgium
- Volunteers
- 152 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.